@article{22855998cdf34b52963cf9383911bb5f,
title = "The application of toxins and venoms to cardiovascular drug discovery",
abstract = "Animal venoms contain a variety of highly selective and potent toxins, which have evolved over thousands/millions of years, which target vital physiological processes. As such, they have proven to be an excellent source of lead compounds for the development of therapeutic agents. In particular, a number of these venom components (e.g. bradykinin-potentiating peptides, sarafotoxins, natriuretic peptides) have profound effects on the cardiovascular system. This review article examines recent progress in the search for lead compounds or novel scaffolds for cardiovascular drug development from animal venoms. � 2008 Elsevier Ltd. All rights reserved.",
keywords = "antiarrhythmic agent, atrial natriuretic factor, bradykinin potentiating peptide, brain natriuretic peptide, cardiovascular agent, dipeptidyl carboxypeptidase inhibitor, exendin 4, fish venom, glitazone derivative, metformin, natriuretic peptide type C, peptide derivative, sarafotoxin, snake venom, spider venom, sulfonylurea, toxin, unclassified drug, venom, acute heart failure, acute heart infarction, antihypertensive activity, cardiovascular disease, cardiovascular risk, clinical trial, diabetes control, drug design, drug isolation, drug mechanism, drug structure, enzyme inhibition, heart arrhythmia, heart atrium fibrillation, human, hyperglycemia, non insulin dependent diabetes mellitus, nonhuman, pathophysiology, priority journal, review, risk reduction, structure activity relation, unspecified side effect, Animals, Anti-Arrhythmia Agents, Cardiovascular Diseases, Drug Discovery, Humans, Incretins, Natriuretic Peptides, Oligopeptides, Toxins, Biological, Viper Venoms",
author = "W HODGSON and Geoffrey Isbister",
year = "2009",
language = "English",
volume = "9",
pages = "173--176",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier",
number = "2",
}